AngA-modified bone marrow mesenchymal stem cell-derived small extracellular vesicles-liposome hybrid nanoparticles loaded with Glabridin protect against doxorubicin-induced cardiotoxicity by enhancing autophagic flux via the ATG5–ATG12–ATG16L1 comple

Doxorubicin-induced cardiotoxicity (DIC) limits its clinical application and poses a significant risk to cancer patients, with impaired autophagic flux considered a core mechanism underlying DIC. Although glabridin (Gla) exhibits prominent cardioprotective effects, its poor water solubility and limited myocardial-targeting capability hinder its clinical translation. Therefore, improving the myocardial-targeting properties of Gla and restoring autophagy are critical for the treatment of DIC. In this study, we prepared angiotensin A (AngA)‑modified bone marrow mesenchymal stem cell (BMSC)-derived small extracellular vesicle (sEV)‑liposome hybrid nanoparticles and loaded them with Gla (AngA-sEV-Lip@Gla). We evaluated their myocardial-targeting capability, therapeutic efficacy against DIC, and ability to restore autophagic flux. Click chemistry-activity-based protein profiling (CC-ABPP) and site-directed mutagenesis were employed to identify the molecular target and signaling pathway of Gla. Our results demonstrated the successful establishment of AngA-sEV-Lip@Gla. In vitro and in vivo experiments showed that AngA-sEV-Lip@Gla efficiently targeted myocardial tissue and achieved favorable lysosomal escape. AngA-sEV-Lip@Gla also markedly alleviated DOX-induced cardiomyocyte injury, oxidative stress, and mitochondrial dysfunction, while ameliorating cardiac dysfunction, myocardial pathological damage, and fibrosis in DIC model mice. Mechanistic studies indicated that Gla might act at the MET173 site of ATG5 to upregulate the expression of the ATG5–ATG12–ATG16L1 complex, thereby restoring blocked autophagic flux in cardiomyocytes and exerting cardioprotective effects. In summary, AngA-sEV-Lip@Gla targets the MET173 site of ATG5 to modulate the ATG5–ATG12–ATG16L1 complex and restore autophagic flux, thereby effectively protecting against DIC. Our study provides novel mechanistic insights and experimental support for the clinical prophylaxis and treatment of DIC.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-18
DOI
https://doi.org/10.1186/s12951-026-05275-4
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AngA-modified bone marrow mesenchymal stem cell-derived small extracellular vesicles-liposome hybrid nanoparticles loaded with Glabridin protect against doxorubicin-induced cardiotoxicity by enhancing autophagic flux via the ATG5–ATG12–ATG16L1 comple

Liang Kong, Ruibo Guo, Xuetao Li, Liyan Wang et al.
3 links
Journal of Nanobiotechnology
Nanoparticle-Based Drug Delivery
article

AngA-modified bone marrow mesenchymal stem cell-derived small extracellular vesicles-liposome hybrid nanoparticles loaded with Glabridin protect against doxorubicin-induced cardiotoxicity by enhancing autophagic flux via the ATG5–ATG12–ATG16L1 comple

Liang Kong, Ruibo Guo, Xuetao Li, Liyan Wang, Yani Zhang, Yi-fei Gao, Zheng Li, Ying Zheng, Jia-hua Wang
article en

Abstract

Doxorubicin-induced cardiotoxicity (DIC) limits its clinical application and poses a significant risk to cancer patients, with impaired autophagic flux considered a core mechanism underlying DIC. Although glabridin (Gla) exhibits prominent cardioprotective effects, its poor water solubility and limited myocardial-targeting capability hinder its clinical translation. Therefore, improving the myocardial-targeting properties of Gla and restoring autophagy are critical for the treatment of DIC. In this study, we prepared angiotensin A (AngA)‑modified bone marrow mesenchymal stem cell (BMSC)-derived small extracellular vesicle (sEV)‑liposome hybrid nanoparticles and loaded them with Gla (AngA-sEV-Lip@Gla). We evaluated their myocardial-targeting capability, therapeutic efficacy against DIC, and ability to restore autophagic flux. Click chemistry-activity-based protein profiling (CC-ABPP) and site-directed mutagenesis were employed to identify the molecular target and signaling pathway of Gla. Our results demonstrated the successful establishment of AngA-sEV-Lip@Gla. In vitro and in vivo experiments showed that AngA-sEV-Lip@Gla efficiently targeted myocardial tissue and achieved favorable lysosomal escape. AngA-sEV-Lip@Gla also markedly alleviated DOX-induced cardiomyocyte injury, oxidative stress, and mitochondrial dysfunction, while ameliorating cardiac dysfunction, myocardial pathological damage, and fibrosis in DIC model mice. Mechanistic studies indicated that Gla might act at the MET173 site of ATG5 to upregulate the expression of the ATG5–ATG12–ATG16L1 complex, thereby restoring blocked autophagic flux in cardiomyocytes and exerting cardioprotective effects. In summary, AngA-sEV-Lip@Gla targets the MET173 site of ATG5 to modulate the ATG5–ATG12–ATG16L1 complex and restore autophagic flux, thereby effectively protecting against DIC. Our study provides novel mechanistic insights and experimental support for the clinical prophylaxis and treatment of DIC.

Journal of Nanobiotechnology
Liaoning University of Traditional Chinese Medicine (CN), Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (CN), China Academy of Chinese Medical Sciences (CN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon